Christopher Rohde
Member of Scientific Advisory BoardDr. Christopher Rohde, Ph.D., serves as Chris, serves as Member of Scientific Advisory Board at Ernexa Therapeutics Inc. (formerly known as Eterna Therapeutics Inc.) (formerly known as Brooklyn ImmunoTherapeutics, Inc.) since May 13, 2021. Dr. Rohde is the Co-Founder of Novellus Therapeutics Limited. He serves as CTO at Factor Bioscience Inc and also serves as it's Co-Founder from, 2021. He has been Scientific Advisory Board Member at Exacis Biotherapeutics Inc. Dr. Rohde serves as Director at Novellus LLC. Dr. Rohde is Co-Founder and Chief Technology Officer at Factor Bioscience. Dr. Rohde is also Co-Founder and President of Novellus Therapeutics. Brooklyn ImmunoTherapeutics acquired an exclusive license for the mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited. Dr. Rohde is currently leading Factor?s efforts to apply their RiboSlice? gene-editing technology, and FactorStem? cell-reprogramming and differentiation technologies to the development of new research models, including high-throughput screening-compatible human cell libraries. His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many other publications. Dr. Rohde earned his Ph.D. from the Massachusetts Institute of Technology (MIT) in 2011.
Positions
- Company NameErnexa Therapeutics Inc.Stock CodeERNAPositionMember of Scientific Advisory BoardRelated SecuritiesColleagues
- SLSanjeev LutherCEO, President & Director
- JAJames A. BristolIndependent Chairman of the Board
- MJMark J. KeeleyChief Financial Officer
- DVDeborah Vee WildHead of CMC & Operations
- RHRobert Hamilton PierceChief Scientific Officer
- DJDorothy J. ClarkeGeneral Counsel
- WAWilliam A. WexlerIndependent Director
- MAMichael AndreeffMember of Scientific Advisory Board
